|
|
|
| Value of DSA and Gadolinium Bemeglumine Enhanced MRI in the Diagnosis of Small Recurrent Lesions of Hepatocellular Carcinoma after TACE |
| MI Lei, YANG Xing-liang, HUANG Shi-quan |
| The First Hospital of Yulin,Yulin Shaanxi 718000 |
|
|
|
|
Abstract 【Objective】To investigate the diagnostic efficacy of digital subtraction angiography (DSA) and gadolinium enhanced magnetic resonance imaging (MRI) in the recurrence of small lesions after transcatheter arterial chemoembolization (TACE) of liver cancer. 【Methods】A total of 85 HCC patients treated with TACE in our hospital from January 2017 to January 2021 were selected. All patients were examined with DSA and gadolinium enhanced MRI, and the pathological results were taken as the recurrence results of small liver cancer. The results of DSA and gadolinium enhanced MRI in the diagnosis of recurrence of small liver cancer were recorded, and the efficacy of the two diagnostic methods was analyzed. 【Results】After TACE, 41 out of 85 HCC patients (48.2%) were confirmed to have relapsed small lesions by biopsy. DSA and gadolinium bemeglumine enhanced MRI showed that 38 cases and 39 cases were small recurrent lesions, respectively. The sensitivity and specificity of DSA were 92.7% and 100.0% respectively for the diagnosis of recurrent small lesions, and the sensitivity and specificity of gadolinium bemeglumine enhanced MRI for the diagnosis of recurrent small lesions were 95.1% and 100.0% respectively, with no significant difference (P>0.05). The consistency between DSA and gadolinium bemeglumine enhanced MRI diagnosis and pathological diagnosis was 0.791 and 0.778 respectively, and the consistency between DSA and gadolinium bemeglumine enhanced MRI diagnosis was 0.802. 【Conclusion】DSA and gadolinium bemeglumine enhanced MRI have similar efficacy in the diagnosis of small recurrent lesions of hepatocellular carcinoma after TACE, and suitable diagnostic methods can be selected reasonably according to individual conditions.
|
|
Received: 09 March 2022
|
|
|
|
|
|
[1] PRITCHARD W F. Transarterial chemoembolization in a woodchuck model of hepatocellular carcinoma[J].J Vasc Interv Radiol,2020,31(5):812-819.
[2] TATEISHI H.Clinical applications of digital angiography with the harmonization function in body interventional radiology[J].Jpn J Radiol,2020,38(10):922-933.
[3] 苏赞瑞,黄运福,林建军,等. DSA和钆塞酸二钠增强MRI对肝癌术后复发微小病灶诊断的比较研究[J].介入放射学杂志,2017,26(6):559-563.
[4] 杨亮.超声造影与增强MRI在肝细胞癌TACE疗效评估中的应用价值[J].中华肝胆外科杂志,2020,26(9):683-686.
[5] 刘术昌,齐杰,高战强,等. 动态增强CT与数字减影血管造影联合血清甲胎蛋白水平检测对原发性肝癌的诊断价值分析[J].中国医疗设备,2019,34(2):49-50.
[6] HULIN A,STOCCO J,BOUATTOUR M. Clinical pharmacokinetics and pharmacodynamics of transarterial chemoembolization and targeted therapies in hepatocellular carcinoma[J].Clin Pharmacokinet,2019,58(8):983-1014.
[7] LIN Y Y,LEE R C,GUO W Y,et al. Quantitative real-time fluoroscopy analysis on measurement of the hepatic arterial flow during transcatheter arterial chemoembolization of hepatocellular carcinoma:comparison with quantitative digital subtraction angiography analysis[J].Cardiovasc Intervent Radiol,2016,39(11):1557-1563.
[8] SANGHVI T,BOYUM J,SPILSETH B,et al. MRI for hepatocellular carcinoma:a primer for magnetic resonance imaging interpretation[J].Abdom Radiol (NY),2018,43(5):1143-1151.
[9] GUAN W,GAO Z,HUANG C,et al. The diagnostic value of serum DSA-TRF in hepatocellular carcinoma[J].Glycoconj J,2020,37(2):231-240.
[10] RONOT M,PURCELL Y,VILGRAIN V. Hepatocellular carcinoma:current imaging modalities for diagnosis and prognosis[J].Dig Dis Sci,2019,64(4):934-950. |
|
|
|
2022, Vol. 39 
